Londoño F
Med Cutan Ibero Lat Am. 1976;4(6):463-7.
Sixty-four patients were treated for inflammatory dermatoses or cutaneous candidiasis with a new corticosteroid combination drug, halcinonide-neomycin-nystatin (HNN). In 50 patients treated for psoriasis, atopic dermatitis, eczematous dermatitis, or neurodermatitis, HNN was evaluated in a double-blind, paired comparison study with hydrocortisone (HC) as the control drug. HNN was superior in 24 patients, HC was superior in 6, and the responses were equal in 18. The overall therapeutic response was Excellent with HNN in 29 patients as compared to 14 with HC. The anticandidal properties of HNN were assessed in a parallel study with iodochlorhydroxyquin-hydrocortisone (I-HC) as the control drug. The most frequently treated conditions were "erosio interdigitalis blastomycotica" and candidal lesions of the neck region. The response with HNN was Excellent in 7 of 14 patients as compared to 4 out of 14 treated with I-HC.
64名患有炎性皮肤病或皮肤念珠菌病的患者接受了一种新的皮质类固醇复方药物——哈西奈德-新霉素-制霉菌素（HNN）的治疗。在50名接受银屑病、特应性皮炎、湿疹性皮炎或神经性皮炎治疗的患者中，以氢化可的松（HC）作为对照药物，对HNN进行了双盲配对比较研究。24名患者使用HNN疗效更佳，6名患者使用HC疗效更佳，18名患者的反应相同。与使用HC的14名患者相比，29名使用HNN的患者总体治疗反应为优。在一项平行研究中，以碘氯羟喹-氢化可的松（I-HC）作为对照药物，评估了HNN的抗念珠菌特性。最常治疗的病症为“指间糜烂性芽生菌病”和颈部念珠菌病损。与接受I-HC治疗的14名患者中的4名相比，接受HNN治疗的14名患者中有7名反应为优。
